Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

CD33 is expressed on the majority of acute myeloid leukemia (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33 mAb. In the present study, we quantified the CD33 mean fluorescent intensity of leukemic blasts prospectively in 619 de novo pediatric AML...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Pollard, Jessica A., Alonzo, Todd A., Loken, Michael, Gerbing, Robert B., Ho, Phoenix A., Bernstein, Irwin D., Raimondi, Susana C., Hirsch, Betsy, Franklin, Janet, Walter, Roland B., Gamis, Alan, Meshinchi, Soheil
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2012
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3335378/
https://ncbi.nlm.nih.gov/pubmed/22378848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-398370
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia